News and Updates

Explore Medicines360’s latest news and resources

FEATURED UPDATES

Press Releases

FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years

Approval Offers Women Additional Flexibility for Pregnancy Prevention DUBLIN and SAN FRANCISCO – Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use […]

Read More >

Press Releases

FDA Acceptance of Medicines360’s Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Application Seeks to Extend Duration of Use Up to 5 Years for LILETTA DUBLIN and SAN FRANCISCO – Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360’s […]

Read More >
Press Releases

Study Finds Z-CAN Program, Supported by Medicines360, Increased Use of LARCs by Women in Puerto Rico During Zika Outbreak

Access to Full Range of Contraception, Plus Patient-Centered Counseling, Successful Formula for Woman-led Prevention of Unintended Pregnancy SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today highlighted a new report published in The Lancet Public Health. The report examined the effectiveness of the CDC […]

Read More >
Press Releases

FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years

Approval Offers Women Additional Flexibility for Pregnancy Prevention DUBLIN and SAN FRANCISCO – Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use […]

Read More >